-
[Latest] Global Lung Tumor Market Size/Share Worth USD 46.3 Billion by 2033 at a 7.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
15 Apr 2024 16:30 GMT
… lung tumor diagnosis. This delay could result in the diagnosis of lung tumors … Reports: Lung Cancer Liquid Biopsy Market: Lung Cancer Liquid Biopsy … Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other Monoclonal …
-
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
02 Apr 2024 20:15 GMT
… , recurrent non-small cell lung cancer (“NSCLC”) who have previously … with non-small cell lung cancer (“NSCLC”) that cannot … patients with inoperable, recurrent lung cancer and patients amenable to … therapy, with or without cetuximab, for the treatment of …
-
Bristol Myers announces positive results from phase 1/ 2 KRYSTAL─1 study of Krazati in combo with cetuximab to treat patients with previously treated KRASG12C─mutated locally advanced or metastatic CRC
10 Apr 2024 10:19 GMT
… adagrasib) in combination with cetuximab for the treatment of … 94 patients, Krazati plus cetuximab demonstrated an objective response … metastatic non-small cell lung cancer (NSCLC), as determined … metastatic non-small cell lung cancer (NSCLC), as determined …
-
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
08 Apr 2024 15:42 GMT
… adagrasib) in combination with cetuximab for the treatment of … patients, KRAZATI plus cetuximab demonstrated an objective response … metastatic non-small cell lung cancer (NSCLC), as determined … metastatic non-small cell lung cancer (NSCLC), as determined …
-
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
19 Apr 2024 12:46 GMT
… treated advanced non-small cell lung cancer(NSCLC)patients with G12C … of GFH925 in combination with cetuximab is ongoing in Europe … other hot tumors such as lung cancer; more targeted agents with … cancer, and 15-20% lung cancer patients. The occurrence of …
-
US FDA accepts for priority review Bristol Myers' sNDA for Krazati in combo with cetuximab for patients with previously treated KRAS G12C─mutated locally advanced or metastatic CRC
22 Feb 2024 05:58 GMT
… adagrasib) in combination with cetuximab for the treatment of … profile for Krazati plus cetuximab was manageable and consistent … or metastatic non-small cell lung cancer (NSCLC), as determined … metastatic non-small cell lung cancer (NSCLC), as determined …
-
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...
20 Feb 2024 12:13 GMT
… adagrasib) in Combination with Cetuximab as a Targeted Treatment … metastatic non-small cell lung cancer (NSCLC), as determined … metastatic non-small cell lung cancer (NSCLC), as determined … adagrasib) in combination with cetuximab may not receive regulatory …
-
Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy
17 Apr 2024 07:31 GMT
… in an EGFR-mutated lung cancer patient. Lung Cancer. 2016;95:35– … complicating the use of cetuximab and panitunumab. Int J … advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: … epidermal necrolysis in a lung cancer patient harboring an EGFR …
-
Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches
21 Dec 2023 04:45 GMT
… lung cancers. The two broad histological subtypes of lung cancer are small cell lung cancer … specifically accumulate in lung tumor tissues, improving drug … targeted delivery to lung tumors is a … Cetuximab in the treatment of advanced non-small cell lung cancer …
-
US FDA approves Pfizer's encorafenib+binimetinib for BRAF V600E─mutant metastatic non─small cell lung cancer
16 Oct 2023 04:06 GMT
… medicines to patients with lung cancer. By pursuing precision medicines … metastatic non-small cell lung cancer that presents an … approved, in combination with cetuximab, for the treatment of … -85% of all lung cancers.
Certain lung cancers are linked to …